PMV Pharmaceuticals (PMVP) Proxy filing summary

Executive summary

• The annual meeting will be held virtually on June 4, 2026, with voting available online, by phone, or by mail.

• Stockholders will vote on electing two Class III directors, approving executive compensation on an advisory basis, and ratifying the appointment of Ernst & Young LLP as the independent auditor.

• The board recommends voting in favor of all proposals.

• Proxy materials are primarily distributed electronically to expedite delivery and reduce costs.

Voting matters and shareholder proposals

• Proposals include electing David H. Mack, Ph.D. and Laurie Stelzer as Class III directors, a non-binding say-on-pay vote, and ratification of Ernst & Young LLP as auditor.

• Shareholders may submit additional proposals or nominations for the 2027 meeting by specified deadlines.

• Each share of common stock is entitled to one vote per proposal; cumulative voting is not permitted.

Board of directors and corporate governance

• The board will reduce from seven to six members after Dr. Heyman's term ends; Laurie Stelzer will become chairperson.

• The board is divided into three classes with staggered three-year terms.

• Six of seven directors are independent; Dr. Mack is not independent as CEO.

• Board committees include audit, compensation, and nominating/governance, each with independent members and written charters.

• The board encourages diversity and considers a range of qualifications for director nominees.